Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market to Witness Promising Growth, Opportunities and Forecast
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market size was estimated at USD 7,820 million in 2023 and is projected to reach USD 13,753.5 million in 2030 at a CAGR of 8.40% during the forecast period 2024-2030.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare, progressive autoimmune disorder characterized by the inflammation of peripheral nerves, leading to demyelination, motor weakness, sensory loss, and in some cases, severe disability. It is considered the most common type of chronic acquired neuropathy and affects both adults and children.
Get Free Sample Report: https://www.delvens.com/get-free-sample/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
The exact cause of CIDP remains unclear, but it is thought to involve the body’s immune system mistakenly attacking its own nerves. Although CIDP is treatable with immunomodulatory therapies, its progressive nature and the potential for long-term disability without proper management highlight the importance of early diagnosis and sustained treatment regimens.
North America to Dominate the Market
North America led the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market in 2021, capturing over 44.90% of the total revenue. The region's growth is expected to continue, driven by the approval and launch of new immunotherapy treatments and favourable reimbursement policies. For example, in October 2021, Merck’s Keytruda, an anti-PD-1 therapy, received FDA approval in combination with chemotherapy for cervical cancer. Additionally, in August 2021, Bristol Myers Squibb's OPDIVO (nivolumab) was approved by the FDA for treating urothelial carcinoma.
The prominent players in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market are
·??????? F. Hoffmann-La Roche Ltd.
·??????? Mylan N.V.
·??????? Teva Pharmaceutical Industries Ltd.
·??????? Sanofi
·??????? Pfizer Inc.
·??????? GSK plc
·??????? Novartis AG
·??????? AstraZeneca
·??????? Johnson & Johnson Private Limited
·??????? Sun Pharmaceutical Industries Ltd.
·??????? Merck & Co., Inc.
·??????? Lilly
·??????? Amgen Inc.
·??????? Actelion Pharmaceuticals Ltd. and More
For More Inquiry Contact us: https://www.delvens.com/Inquire-before-buying/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is driven by increasing awareness, advancements in diagnostic tools, and the growing adoption of targeted treatments such as immunoglobulin therapies and biologics. CIDP, a rare autoimmune disorder causing progressive nerve damage, is becoming more diagnosable as healthcare systems improve globally, expanding the potential market for treatments. Key trends include the shift towards precision medicine and personalized therapies, fuelled by genetic and biomarker research. The market is also supported by rising autoimmune disease prevalence and ongoing drug development, although challenges such as high treatment costs and limited healthcare access in certain regions may impact growth. As better treatments and earlier diagnosis emerge, the CIDP market is expected to continue expanding in the coming years.
Recent Developments
In June 2022, Bio Products Laboratory (BPL) obtained marketing authorization for Congaed in the Dominican Republic, a key milestone in the treatment of Hereditary Factor X Deficiency.
领英推荐
In February 2022, Grifols partnered with Endpoint Health, Inc. to develop an Antithrombin III (AT-III) therapy for Sepsis.
Furthermore, in January 2022, Janssen Pharmaceutical teamed up with SRI International to utilize SRI's SynFin platform in small molecule drug discovery, aiming to advance research into complex neurological disorders, including CIDP.
The Report helps to identify the opportunities in Global Regions:
·??????? North America (the United States, Canada, and Mexico)
·??????? Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
·??????? Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
·??????? South America (Brazil etc.)
·??????? The Middle East and Africa (North Africa and GCC Countries)
Access Full Report: https://www.delvens.com/report/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
Frequently Asked Questions
What are the years considered to study Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market intelligence report?
What is the compound annual growth rate (CAGR) of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Which region holds the largest market share in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Which region is the fastest growing in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Who are the major players in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
In addition to the market data for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Delvens offers client-centric report and customized according to the company’s specific demand and requirement.
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
Unit No. 01, 3rd Floor, Plot No. 56, Block B
Sector 2 Noida, Near Noida Sector 15 Metro Station 201301, IN
+44 20 3290 6466
+0120- 4903958